A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer
Status:
Recruiting
Trial end date:
2023-04-26
Target enrollment:
Participant gender:
Summary
The reason for this study is to see if the study drug LY3484356 alone or in combination with
other anticancer therapies is safe and effective in participants with advanced or metastatic
breast cancer or endometrial cancer.